NASDAQ:SPRC SciSparc Q2 2025 Earnings Report $8.84 -1.75 (-16.53%) As of 02:27 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast SciSparc EPS ResultsActual EPS-$27.73Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASciSparc Revenue ResultsActual Revenue$0.23 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASciSparc Announcement DetailsQuarterQ2 2025Date11/18/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile SciSparc Earnings HeadlinesSciSparc Ltd. Ordinary Shares (SPRC) SEC FilingsMay 30 at 8:00 PM | nasdaq.comSciSparc Ltd: SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantumMay 29, 2026 | finanznachrichten.de"You'll own nothing and be happy" (it's not a theory anymore)On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.June 2 at 1:00 AM | Decentralized Masters (Ad)SciSparc jumps 150.8% as subsidiary wins conditional exchange approval for CliniQuantum dealMay 28, 2026 | quiverquant.comQWhy Is SciSparc Stock Skyrocketing On Thursday?May 28, 2026 | benzinga.comSciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantumMay 28, 2026 | globenewswire.comSee More SciSparc Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SciSparc? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SciSparc and other key companies, straight to your email. Email Address About SciSparcSciSparc (NASDAQ:SPRC) AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline. The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function. By harnessing acoustic pressure waves, the TR100 aims to promote neurogenesis and synaptic plasticity without the need for surgical intervention. SciSparc has obtained CE marking for its tSWS platform in the European Union and is actively pursuing clinical trials in indications such as post‐stroke motor rehabilitation, treatment‐resistant depression and other neurological disorders. Serving both European and North American markets, SciSparc collaborates with academic institutions and clinical research centers to validate safety and efficacy in human subjects. Its Swiss headquarters oversees research and development, regulatory affairs and manufacturing partnerships, while its U.S. operations concentrate on clinical development and market access strategies. By integrating neuroscience research with advanced engineering, SciSparc aims to expand the availability of noninvasive neuromodulation therapies on a global scale.View SciSparc ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Dollar General Signals Reversal With 60% Rebound PotentialKohl's Stock Soars After Better-Than-Feared QuarterCredo Technologies Paved a Path to a $300 Price PointHubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to WaitBraze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceDrone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name Upcoming Earnings Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
